Sitagliptin/Metformin Sustained Release Tablet 50/500 mg

Adult dose

The dosage for this sustained release form of the drug 100/1000 mg is 1 tablet once daily. For patients using the 50/500 mg or 50/1000 mg sustained release forms, 2 tablets are to be taken simultaneously once daily. 1. For patients not currently treated with metformin: The initial dosage is a total daily amount of sitagliptin 100 mg and metformin 1000 mg. If adequate blood sugar control is not achieved with the initial dosage, metformin may be gradually increased to its maximum recommended dose of 2000 mg while reducing the likelihood of gastrointestinal side effects.

This medication contains two components, sitagliptin and metformin, and is primarily used for the treatment of type 2 diabetes. First, while sitagliptin helps with blood sugar control, it can rarely cause severe allergic reactions. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within 3 months of use, it is essential to stop using the medication immediately and consult a doctor. Also, sitagliptin can cause acute pancreatitis, so if symptoms like abdominal pain, vomiting, or severe indigestion occur, medication should be stopped immediately, and the patient should visit a hospital. Metformin has blood sugar-lowering effects but should not be administered to patients with severely impaired kidney function, dehydration, severe infections, or heart disease. Regular kidney function tests should be performed, particularly for these patients. This medication can pose a risk of lactic acidosis, a rare but life-threatening metabolic disorder. If symptoms such as sudden fatigue, muscle pain, difficulty breathing, abdominal pain, or confusion occur, the healthcare provider should be notified immediately. Excessive alcohol consumption can increase the risk of side effects from this medication, so alcohol should be avoided. Before surgery or radiological contrast examinations, patients should consult with their physician about temporarily discontinuing the medication and should resume it after kidney function has recovered. This medication should not be administered to pregnant or breastfeeding women, and its safety in individuals under 18 years of age has not been established. There is a risk of hypoglycemia while taking this medication, so especially if taken with other blood sugar-lowering agents, blood sugar levels should be checked frequently, and if unusual symptoms occur, the doctor should be consulted immediately. While taking this medication, regular blood tests and kidney function tests should be conducted to monitor for adverse reactions, and vitamin B12 levels may decrease, necessitating supplementation if required. Lastly, if an overdose of this medication is suspected, the patient should visit a hospital immediately for appropriate treatment, as some components may be removed by dialysis.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, rash, high fever, blisters, skin peeling, pain in mucous membranes of the mouth/eyes, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, acute renal failure, liver abnormalities (jaundice), elevated liver enzymes, severe neurological symptoms (severe headache, seizures, confusion, vision disturbances, paralysis), hypoxemia, severe edema accompanied by elevated blood pressure, acute

Mild side effects

• Diarrhea
• nausea
• vomiting
• abdominal pain
• upper respiratory infection
• nasopharyngitis
• headache
• hypoglycemia
• myalgia
• limb pain

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.

Appearance

Bright blue, biconvex, oval-shaped sustained release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle